BerGenBio
Clinical-stage biopharma that developed selective AXL kinase inhibitors for cancer.
BGBIO | OL
Overview
Corporate Details
- ISIN(s):
- NO0012921180 (+2 more)
- LEI:
- 213800TYYFXKYF3V2A23
- Country:
- Norway
- Address:
- MØLLENDALSBAKKEN 9, 5009 BERGEN
- Website:
- https://www.bergenbio.com/
- Sector:
- Manufacturing
Description
BerGenBio was a clinical-stage biopharmaceutical company focused on developing first-in-class selective AXL kinase inhibitors. The company's therapeutic candidates targeted AXL as a potential cornerstone of therapy for aggressive, advanced, and treatment-resistant cancers. In October 2025, BerGenBio completed a merger with Oncoinvent ASA, and the combined entity was renamed Oncoinvent.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2020-09-24 18:26 |
BERGENBIO FÅR GODKJENNING FRA REK (REGIONAL ETISK KOMITÉ) FOR COVID-19 FORSØK I…
|
Norwegian | 4.6 KB | ||
| 2020-09-24 18:25 |
BERGENBIO RECEIVES APPROVAL FROM NORWEGIAN REGIONAL ETHICS COMMITTEE FOR COVID-…
|
Norwegian | 35.5 KB | ||
| 2020-09-24 18:25 |
BERGENBIO RECEIVES APPROVAL FROM NORWEGIAN REGIONAL ETHICS COMMITTEE FOR COVID-…
|
English | 4.8 KB | ||
| 2020-09-18 05:00 |
BERGENBIO TO PRESENT AT SACHS ANNUAL BIOTECH IN EUROPE FORUM
|
English | 35.5 KB | ||
| 2020-09-18 05:00 |
BERGENBIO TO PRESENT AT SACHS ANNUAL BIOTECH IN EUROPE FORUM
|
English | 4.5 KB | ||
| 2020-09-11 13:31 |
OSLO BØRS - MATCHING HALT ENDS
|
English | 367 bytes | ||
| 2020-09-11 13:25 |
BERGENBIO FÅR GODKJENNING TIL Å STARTE FASE II FORSØK AV BEMCENTINIB FOR COVID-…
|
Norwegian | 219.4 KB | ||
| 2020-09-11 13:25 |
BERGENBIO FÅR GODKJENNING TIL Å STARTE FASE II FORSØK AV BEMCENTINIB FOR COVID-…
|
Norwegian | 6.4 KB | ||
| 2020-09-11 13:25 |
BERGENBIO RECEIVES APPROVAL TO COMMENCE PHASE II TRIAL OF BEMCENTINIB FOR COVID…
|
English | 232.9 KB | ||
| 2020-09-11 13:25 |
BERGENBIO RECEIVES APPROVAL TO COMMENCE PHASE II TRIAL OF BEMCENTINIB FOR COVID…
|
English | 6.4 KB | ||
| 2020-09-11 13:22 |
Matching Halt
|
English | 278 bytes | ||
| 2020-09-01 05:00 |
BERGENBIO TO PRESENT AT UPCOMING INVESTOR CONFERENCES
|
English | 215.0 KB | ||
| 2020-09-01 05:00 |
BERGENBIO TO PRESENT AT UPCOMING INVESTOR CONFERENCES
|
English | 5.7 KB | ||
| 2020-08-19 14:30 |
BerGenBio ASA: Primary Insider notification
|
English | 672 bytes | ||
| 2020-08-18 05:02 |
BERGENBIO ASA: RESULTS FOR THE SECOND QUARTER AND FIRST HALF OF 2020
|
English | 7.6 MB |
Automate Your Workflow. Get a real-time feed of all BerGenBio filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BerGenBio
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BerGenBio via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
